CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-31 | Heerma Peter Chief Commercial Officer | Grant or award · Performance-based restricted stock units | +8,000 | 8,000 | ||
| 2022-01-31 | Clague Laura Chief Financial Officer | Grant or award | +9,840 | 39,093 | ||
| 2022-01-31 | Clague Laura Chief Financial Officer | Sale | −1,238 | $27.40 | $34K | 37,855 |
| 2022-01-31 | Clague Laura Chief Financial Officer | Grant or award · Employee stock option (right to buy) | +39,360 | 39,360 | ||
| 2022-01-31 | Clague Laura Chief Financial Officer | Grant or award · Performance-based restricted stock units | +9,840 | 9,840 | ||
| 2022-01-31 | Clague Laura Chief Financial Officer | Grant or award · Performance-based restricted stock units | +8,000 | 8,000 | ||
| 2022-01-31 | Dube Eric M Chief Executive Officer | Grant or award | +37,848 | 169,558 | ||
| 2022-01-31 | Dube Eric M Chief Executive Officer | Sale | −4,813 | $27.40 | $132K | 164,745 |
| 2022-01-31 | Dube Eric M Chief Executive Officer | Grant or award · Employee stock option (right to buy) | +169,552 | 169,552 | ||
| 2022-01-31 | Dube Eric M Chief Executive Officer | Grant or award · Performance-based restricted stock units | +37,848 | 37,848 | ||
| 2022-01-24 | Calvin Sandra VP, Corp Controller and CAO | Sale | −934 | $24.58 | $23K | 28,662 |
| 2022-01-24 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −1,875 | $24.98 | $47K | 36,520 |
| 2022-01-24 | Heerma Peter Chief Commercial Officer | Sale | −1,875 | $24.98 | $47K | 58,582 |
| 2022-01-24 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −2,250 | $24.98 | $56K | 35,298 |
| 2022-01-24 | Clague Laura Chief Financial Officer | Sale | −2,063 | $24.98 | $52K | 29,253 |
| 2022-01-24 | Dube Eric M Chief Executive Officer | Sale | −7,873 | $24.98 | $197K | 131,710 |
| 2022-01-11 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −5,000 | $27.40 | $137K | 37,548 |
| 2022-01-11 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −2,500 | $27.40 | $69K | 38,395 |
| 2022-01-11 | Clague Laura Chief Financial Officer | Sale | −7,500 | $27.40 | $206K | 31,316 |
| 2022-01-10 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award | +5,000 | 42,548 |
Page 32 of 51 · 1,020 trades